(UroToday.com) Prostate cancer is the most commonly diagnosed male malignancy, developing in one out of nine men during their lifetime. Metastasis free survival has been shown to be a robust surrogate for overall survival in men with non-metastatic prostate cancer. However, this surrogate only holds true for a select subset of patients and leaves those trials analyzing metastatic disease at a disadvantage.